NCT Number: NCT02746159
Lutonix® Global AV Registry Investigating Lutonix Drug Coated Balloon for Treatment of Native and Synthetic AV Fistulae
The purpose of this Registry is to enroll patients presenting with clinical and hemodynamic abnormalities in native or synthetic (grafts) arteriovenous (AV) fistulae located in the arm. Subjects will be treated with the Lutonix DCB carrying the CE Mark per current IFU and followed clinically for a minimum of 12 months.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
LKH Graz, Graz, Austria
About this study
This post market registry is intended to demonstrate safety and assess the clinical use and outcomes of the Lutonix DCB in a heterogeneous patient population with dysfunctional native or synthetic AV fistulae in real world clinical practice.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or non-pregnant, non-breastfeeding female ≥18 years of age;
- Patient is willing to provide informed consent, and is willing to comply with the protocol-required follow up visits;
- Native or synthetic (grafts) arteriovenous fistula located in the arm, including central veins, presenting with any clinical, physiological or hemodynamic abnormalities warranting angiographic imaging as defined in the K/DOQI guidelines; and
- Lesion(s) can be treated with available Lutonix DCB device size matrix per current IFU.
Exclusion criteria
Patients will be excluded if ANY of the following conditions apply:
- Patient is currently participating in an investigational drug or device study which has not yet reached its primary endpoint or was previously enrolled into this registry (i.e. Lutonix Global AV registry).
- Patient has a non-controllable allergy to contrast; or
- Patient has another medical condition that, which in the opinion of the Investigator, may confound the data interpretation of is associated with a life expectancy insufficient to allow for completion of patient registry procedure and follow up.
Treatment and study plan
Primary outcomes
-
Proportion of subjects with freedom from any serious adverse event(s) involving the AV access circuit
Time frame: 30 days.
Primary safety events include any serious adverse event(s) involving the AV access circuit
-
Proportion of subjects with target lesion primary patency
Time frame: 6 Months
Defined as the interval following index procedure until clinically-driven reintervention of the target lesion or access thrombosis, through 6 months.
Clinically-driven reintervention is defined as a lesion that has ≥50% stenosis and at least one clinical, physiological or hemodynamic abnormality attributable to the stenosis defined in the K/DOQI guidelines.
Secondary outcomes
-
Proportion of subjects with access circuit primary patency at 3, 6, and 12 months
Time frame: 12 months
Interval following intervention until the next access circuit thrombosis or repeated intervention. Ends with treatment of a lesion anywhere within the access circuit.
-
Proportion of Subjects withTarget Lesion Primary Patency (TLPP)
Time frame: 12 months
Target Lesion Primary Patency (TLPP) is defined as the interval following index procedure intervention until clinically driven reintervention of the target lesion or access thrombosis.
-
Proportion of Subjects with Abandonment of permanent access in the index extremity
Time frame: 12 months
The arteriovenous fistula / access circuit is considered abandoned when it is no longer being used for dialysis because the access was not functioning.
-
Proportion of Subjects with Device Success
Time frame: 12 Months
Successful delivery to the target lesion, deployment, and retrieval at index procedure. If a device is inserted into the subject but not used due to user error (e.g. inappropriate balloon length or transit time too long), this device will not be included in the device success assessment.
-
Proportion of Subjects with Procedural Success
Time frame: 12 Months
At least one indicator of hemodynamic success (e.g., physical examination with restoration of a thrill, direct measurement of flow) in the absence of peri-procedural (index procedure and through hospital stay) Serious Adverse Device Effects (SADEs).
-
Proportion of Subjects with Clinical Success
Time frame: 12 Months
The resumption of dialysis for at least one session after the index procedure.
-
Rate of device and procedure related adverse events
Time frame: 12 months
Freedom from device-related or procedure-related serious adverse events
Sponsors and collaborators
Lead sponsor
C. R. Bard
Industry
Registry information
Official study title
A Prospective, Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon PTA Catheter for Treatment of Dysfunctional Native and Synthetic AV Fistulae
Acronym: AVR
Important dates
- Study start
- 2016
- Primary completion
- 2018
- Study completion
- 2019
- First posted
- Apr 21, 2016
- Registry last updated
- Feb 22, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Virtual Reality Distraction for Pain and Anxiety in Hemodialysis Patients
NCT07334522
Agnosia, Anxiety
Karbala, Iraq
View Trial DetailsOptimizing Access Surgery In Senior Hemodialysis Patients
NCT05911451
Arteriovenous Fistula, Arteriovenous Graft
Alkmaar, Netherlands
View Trial DetailsProspective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae
NCT04896476
Arteriovenous Fistula, Arteriovenous Malformations
Dothan, Alabama, United States
View Trial DetailsSimulation-based Training for Nurses and Arteriovenous Fistula Puncture in Chronic Hemodialysis Patients
NCT05302505
Arteriovenous Fistula, Arteriovenous Malformations
Alençon, France
View Trial Details